JP2011526247A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526247A5 JP2011526247A5 JP2011515027A JP2011515027A JP2011526247A5 JP 2011526247 A5 JP2011526247 A5 JP 2011526247A5 JP 2011515027 A JP2011515027 A JP 2011515027A JP 2011515027 A JP2011515027 A JP 2011515027A JP 2011526247 A5 JP2011526247 A5 JP 2011526247A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- group
- independently
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
- 108010002459 HIV Integrase Proteins 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 2
- 229960003586 elvitegravir Drugs 0.000 claims description 2
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 claims description 2
- 229940124524 integrase inhibitor Drugs 0.000 claims description 2
- 239000002850 integrase inhibitor Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 102220076678 rs146651027 Human genes 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 125000002947 alkylene group Chemical group 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- -1 NR 3 R 4 Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 230000003647 oxidation Effects 0.000 claims 4
- 238000007254 oxidation reaction Methods 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003536 tetrazoles Chemical group 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
- 150000003852 triazoles Chemical group 0.000 claims 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008903406A AU2008903406A0 (en) | 2008-07-02 | Imidazopyrimidinones and uses thereof | |
| AU2008903406 | 2008-07-02 | ||
| US16193109P | 2009-03-20 | 2009-03-20 | |
| US61/161,931 | 2009-03-20 | ||
| PCT/AU2009/000857 WO2010000031A1 (en) | 2008-07-02 | 2009-07-02 | Imidazopyrimidinones and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526247A JP2011526247A (ja) | 2011-10-06 |
| JP2011526247A5 true JP2011526247A5 (enExample) | 2012-03-29 |
| JP5592360B2 JP5592360B2 (ja) | 2014-09-17 |
Family
ID=41465416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515027A Expired - Fee Related JP5592360B2 (ja) | 2008-07-02 | 2009-07-02 | イミダゾピリミジノンおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8431581B2 (enExample) |
| EP (1) | EP2291377B1 (enExample) |
| JP (1) | JP5592360B2 (enExample) |
| CA (1) | CA2729656A1 (enExample) |
| WO (1) | WO2010000031A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318732B2 (en) | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| EP2247601B1 (en) * | 2008-07-02 | 2013-04-10 | Avexa Limited | Thiazopyrimidinones and uses thereof |
| CN102858771A (zh) | 2010-02-26 | 2013-01-02 | 日本烟草产业株式会社 | 1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的用途 |
| US11042897B2 (en) | 2010-08-30 | 2021-06-22 | Adap.Tv, Inc. | System and method for determining effects of multi-channel media sources on multi-channel conversion events |
| US20160002247A1 (en) * | 2013-03-01 | 2016-01-07 | The University Of Tokyo | 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity |
| AU2014262636A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| EA201591962A1 (ru) | 2013-05-10 | 2016-06-30 | Нимбус Аполло, Инк. | Ингибиторы акк и их применение |
| EP2994128B1 (en) | 2013-05-10 | 2019-01-30 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| AU2014262638A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| WO2015064714A1 (ja) * | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| US12195458B2 (en) | 2019-12-02 | 2025-01-14 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| CN116199605A (zh) * | 2023-02-27 | 2023-06-02 | 上海睿腾医药科技有限公司 | 一种5-氯-2-羟基-二甲基苯磺酰胺的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE530520T1 (de) * | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| WO2006103399A1 (en) * | 2005-03-31 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| AR064517A1 (es) * | 2006-12-22 | 2009-04-08 | Avexa Ltd | Pirimidinionas biciclicas y sus usos |
-
2009
- 2009-07-02 WO PCT/AU2009/000857 patent/WO2010000031A1/en not_active Ceased
- 2009-07-02 CA CA2729656A patent/CA2729656A1/en not_active Abandoned
- 2009-07-02 JP JP2011515027A patent/JP5592360B2/ja not_active Expired - Fee Related
- 2009-07-02 US US12/734,042 patent/US8431581B2/en not_active Expired - Fee Related
- 2009-07-02 EP EP09771848.0A patent/EP2291377B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513322A5 (enExample) | ||
| NO20054264L (no) | Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer | |
| RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| JP2011511075A5 (enExample) | ||
| JP2010510999A5 (enExample) | ||
| CA2671127A1 (en) | Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof | |
| JP2011509243A5 (enExample) | ||
| NO20061170L (no) | Piperazinderivater for behandling av HIV-infeksjoner | |
| NZ590126A (en) | Compounds having antiviral properties | |
| HUP0303735A2 (hu) | HIV kezelésére adható pirazolszármazékok és ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására | |
| JP2008528447A5 (enExample) | ||
| CA2487542A1 (en) | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | |
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| JP2006515339A5 (enExample) | ||
| JP2007501831A5 (enExample) | ||
| JP5868955B2 (ja) | 抗ウイルス化合物 | |
| AU2757399A (en) | New use | |
| CA2653830A1 (en) | 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor | |
| JP2009535307A5 (enExample) | ||
| JP2002537292A5 (enExample) | ||
| JP2024538694A5 (enExample) | ||
| RU2314292C2 (ru) | Производные азетидина в качестве антагонистов ccr-3 рецептора | |
| JP2005527521A5 (enExample) | ||
| CA2709839A1 (en) | Fused cyanopryridines and the use thereof | |
| JP2024112835A5 (enExample) |